Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)

Journal of Clinical Lipidology

Volumn 10, Issue 3, 2016, Pages 594-603

  Yeang, Calvin ^a   Hung, Ming Yow ^b,c,d   Byun, Young Sup ^e   Clopton, Paul ^f   Yang, Xiaohong ^a   Witztum, Joseph L ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e Inje University College of Medicine   (South Korea)

^f VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Diet; Ezetimibe; Lipoprotein(a); Niacin; Oxidized phospholipids; Simvastatin; Statin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; NICOTINIC ACID; OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; APHERESIS; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; DRUG EFFECT; EVALUATION STUDY; HUMAN; LOW FAT DIET; METABOLIC SYNDROME X; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT OUTCOME; ADULT; AGED; BLOOD; CONTROLLED STUDY; FEMALE; HYPERLIPIDEMIAS; LITERATURE; MALE; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN B-100; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); MALE; MIDDLE AGED; OXIDATION-REDUCTION; PHOSPHOLIPIDS; REVIEW LITERATURE AS TOPIC; YOUNG ADULT;

EID: 84964282395     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2016.01.005     Document Type: Article

References (55)

1. S. Kiechl, J. Willeit, M. Mayr, and et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study Arterioscler Thromb Vasc Biol 27 2007 1788 1795
2. S. Tsimikas, Z. Mallat, P.J. Talmud, and et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events J Am Coll Cardiol 56 2010 946 955
3. S. Tsimikas, P. Willeit, J. Willeit, and et al. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events J Am Coll Cardiol 60 2012 2218 2229
4. Y.S. Byun, J.H. Lee, B.J. Arsenault, et al. for the TNT Trial Investigators Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: The TNT trial J Am Coll Cardiol 65 2015 1286 1295
5. S. Tsimikas, G.W. Duff, P.B. Berger, and et al. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a) J Am Coll Cardiol 63 2014 1724 1734
6. N. Ahmadi, S. Tsimikas, F. Hajsadeghi, and et al. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium Am J Cardiol 105 2010 459 466
7. M.L. Bertoia, J.K. Pai, J.H. Lee, and et al. Oxidation-specific biomarkers and risk of peripheral artery disease J Am Coll Cardiol 61 2013 2169 2179
8. S. Tsimikas, S. Kiechl, J. Willeit, and et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study J Am Coll Cardiol 47 2006 2219 2228
9. S. Tsimikas, E.S. Brilakis, E.R. Miller, and et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease N Engl J Med 353 2005 46 57
10. S. Tsimikas, C. Bergmark, R.W. Beyer, and et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes J Am Coll Cardiol 41 2003 360 370
11. S. Tsimikas, H.K. Lau, K.R. Han, and et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein Circulation 109 2004 3164 3170
12. P. Willeit, S. Kiechl, F. Kronenberg, and et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study J Am Coll Cardiol 64 2014 851 860
13. K. Arai, M.M. Luke, M.L. Koschinsky, and et al. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles Atherosclerosis 209 2010 498 503
14. F. Rao, A.J. Schork, A.X. Maihofer, and et al. Heritability of biomarkers of oxidized lipoproteins: twin pair study Arterioscler Thromb Vasc Biol 35 2015 1704 1711
15. S. Tsimikas, P. Clopton, E.S. Brilakis, and et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study Circulation 119 2009 1711 1719
16. C. Bergmark, A. Dewan, A. Orsoni, and et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma J Lipid Res 49 2008 2230 2239
17. G. Leibundgut, C. Scipione, H. Yin, and et al. Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a) J Lipid Res 54 2013 2815 2830
18. S. Erqou, A. Thompson, E. Di Angelantonio, and et al. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants J Am Coll Cardiol 55 2010 2160 2167
19. D.A. Tregouet, I.R. Konig, J. Erdmann, and et al. Genome-wide haplotype association study identifies the SLC22A3-LPAL2-LPA gene cluster as a risk locus for coronary artery disease Nat Genet 41 2009 283 285
20. P.R. Kamstrup, A. Tybjaerg-Hansen, R. Steffensen, and B.G. Nordestgaard Genetically elevated lipoprotein(a) and increased risk of myocardial infarction JAMA 301 2009 2331 2339
21. R. Clarke, J.F. Peden, J.C. Hopewell, and et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease N Engl J Med 361 2009 2518 2528
22. R.A. van Dijk, F. Kolodgie, A. Ravandi, and et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions J Lipid Res 53 2012 2773 2790
23. Y.I. Miller, S.H. Choi, P. Wiesner, and et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity Circ Res 108 2011 235 248
24. S. Horkko, D.A. Bird, E. Miller, and et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins J Clin Invest 103 1999 117 128
25. T.A. Seimon, M.J. Nadolski, X. Liao, and et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress Cell Metab 12 2010 467 482
26. N. Leitinger, T.R. Tyner, L. Oslund, and et al. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils Proc Natl Acad Sci U S A 96 1999 12010 12015
27. A. Kadl, A.K. Meher, P.R. Sharma, and et al. Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2 Circ Res 107 2010 737 746
28. R. Capoulade, K.L. Chan, C. Yeang, and et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis J Am Coll Cardiol 66 2015 1236 1246
29. H. Yoshida, T. Shoda, H. Yanai, and et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia Atherosclerosis 226 2013 161 164
30. N. Faghihnia, S. Tsimikas, E.R. Miller, J.L. Witztum, and R.M. Krauss Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet J Lipid Res 51 2010 3324 3330
31. M.J. Budoff, N. Ahmadi, K.M. Gul, and et al. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial Prev Med 49 2009 101 107
32. B. Ky, A. Burke, S. Tsimikas, and et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans J Am Coll Cardiol 51 2008 1653 1662
33. S.H. Choi, A. Chae, E. Miller, and et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study J Am Coll Cardiol 52 2008 24 32
34. J. Rodenburg, M.N. Vissers, A. Wiegman, and et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin J Am Coll Cardiol 47 2006 1803 1810
35. S. Tsimikas, J.L. Witztum, E.R. Miller, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study I High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial Circulation 110 2004 1406 1412
36. M.L. Silaste, M. Rantala, G. Alfthan, and et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a) Arterioscler Thromb Vasc Biol 24 2004 498 503
37. A. Taleb, J.L. Witztum, and S. Tsimikas Oxidized phospholipids on apolipoprotein B-100 (OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events Biomark Med 5 2011 673 694
38. L.A. Carlson, A. Hamsten, and A. Asplund Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid J Intern Med 226 1989 271 276
39. J.J. Albers, A. Slee, K.D. O'Brien, and et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1575 1579
40. J.R. Guyton, B.G. Brown, S. Fazio, A. Polis, J.E. Tomassini, and A.M. Tershakovec Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia J Am Coll Cardiol 51 2008 1564 1572
41. S. Fazio, J.R. Guyton, A.B. Polis, and et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia Am J Cardiol 105 2010 487 494
42. G. Leibundgut, K. Arai, A. Orsoni, and et al. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction J Am Coll Cardiol 59 2012 1426 1437
43. K. Arai, A. Orsoni, Z. Mallat, and et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia J Lipid Res 53 2012 1670 1678
44. S. Tsimikas, N.J. Viney, S.G. Hughes, and et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study Lancet 386 2015 1472 1483
45. M. Croyal, K. Ouguerram, M. Passard, and et al. Effects of extended-release nicotinic acid on apolipoprotein (a) kinetics in hypertriglyceridemic patients Arterioscler Thromb Vasc Biol 35 2015 2042 2047
46. I. Chennamsetty, K.M. Kostner, T. Claudel, and et al. Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice J Lipid Res 53 2012 2405 2412
47. Y.S. Byun, X. Yang, B. Weihang, and et al. Elevated levels of oxidized phospholipids on apolipoprotein B-100 predict recurrent cardiovascular events: a stroke prevention by reduction in cholesterol levels (SPARCL) substudy Abstract presented at the American College of Cardiology Scientific Session J Am Coll Cardiol 65 2015 1286 1295
48. S. Tsimikas, M. Aikawa, F.J. Miller Jr., and et al. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression Arterioscler Thromb Vasc Biol 27 2007 175 181
49. N. Muller, D.M. Schulte, K. Turk, and et al. IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans J Lipid Res 56 2015 1034 1042
50. R.D. Santos, F.J. Raal, A.L. Catapano, J.L. Witztum, E. Steinhagen-Thiessen, and S. Tsimikas Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials Arterioscler Thromb Vasc Biol 35 2015 689 699
51. C. Yeang, J.L. Witztum, and S. Tsimikas 'LDL-C' = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering Curr Opin Lipidol 26 2015 169 178
52. C.P. Cannon, S. Shah, H.M. Dansky, et al. Determining the E, Tolerability I Safety of anacetrapib in patients with or at high risk for coronary heart disease N Engl J Med 363 2010 2406 2415
53. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, T. Anderson, and et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
54. C.P. Cannon, M.A. Blazing, R.P. Giugliano, and et al. Ezetimibe added to statin therapy after acute coronary syndromes N Engl J Med 372 2015 2387 2397
55. K. Briley-Saebo, C. Yeang, J.L. Witztum, and S. Tsimikas Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions J Cardiovasc Transl Res 7 2014 719 736